RxDoctor Payments Data

Son Nguyen, MD

Internal Medicine · Roanoke, VANPI 1780866954

Payments from drug & device makers

$2,297in general payments, 2019–2025

Across 124 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$592
  • Amgen$277
  • Astellas Pharma US Inc$163
  • Abbott$152
  • E.r. Squibb & Sons, L.L.C.$135
  • Johnson & Johnson$125
  • plus $854 from 16 others

What the payments were for

  • Food & beverage$2,297100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,297 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$200,703
Medicare patients
518
Services billed
4,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$79,915
EliquisApixaban35$32,204
OzempicSemaglutide25$29,816
FarxigaDapagliflozin Propanediol18$19,304
TrulicityDulaglutide17$16,710
XareltoRivaroxaban18$11,672
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$3,337
Atorvastatin Calcium271$2,241
Levothyroxine Sodium266$1,983
Albuterol Sulfate HfaAlbuterol Sulfate82$1,960
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc16$1,652
Potassium Chloride112$1,535
Rosuvastatin Calcium172$1,200
Aripiprazole11$1,113
Ezetimibe71$1,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$105$79,91590 claims
PfizerEliquis$60$32,20435 claims
Novo NordiskOzempic$592$29,81625 claims
AstraZenecaFarxiga$57$19,30418 claims
Lilly USA, LLCTrulicity$30$16,71017 claims
Johnson & JohnsonXarelto$125$11,67218 claims
AbbVieSynthroid$91$73516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →